{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:05Z","timestamp":1793040785289,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1053\/j.seminoncol.2009.10.010","type":"journal-article","created":{"date-parts":[[2009,12,5]],"date-time":"2009-12-05T04:11:38Z","timestamp":1259986298000},"page":"S46-S58","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S3","title":["Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials"],"prefix":"10.1053","volume":"36","author":[{"given":"Janet E.","family":"Dancey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Purvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.10.010_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","article-title":"Therapeutic targets: mTOR and related pathways","volume":"5","author":"Dancey","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncponc1173","article-title":"Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the biology of advanced renal cell carcinoma","volume":"5","author":"Figlin","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib4","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib6","series-title":"CCI-779 potentiates the inhibitory effect of the anti-angiogenesis drug interferon-alpha on the growth of a human renal cell carcinoma in nude mice","author":"Gibbons","year":"2006"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib7","first-page":"301","article-title":"The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract 2000]","volume":"40","author":"Gibbons","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib8","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib10","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1158\/0008-5472.CAN-04-4420","article-title":"Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras","volume":"65","author":"Wislez","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-4598-4-25","article-title":"Overcoming cisplatin resistance by mTOR inhibitor in lung cancer","volume":"4","author":"Wu","year":"2005","journal-title":"Mol Cancer"},{"issue":"Suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib12","first-page":"641s","article-title":"Overcoming cisplatin resistance with mTOR inhibition in small cell lung cancer: a phase I-II trial design [abstract 14673]","author":"Bastos","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib13","first-page":"702","article-title":"Biochemical determinants for mTOR inhibitor sensitivity in lung cancer cell lines [abstract 2968]","volume":"48","author":"Wangpaichitr","year":"2008","journal-title":"Proceedings of the 99th Annual Meeting of the American Association of Cancer Research"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbrc.2005.03.166","article-title":"The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation","volume":"331","author":"Asano","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib15","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/ijc.21532","article-title":"In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer","volume":"118","author":"Ito","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib16","first-page":"1758","article-title":"Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition","volume":"7","author":"Dudkin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1593\/neo.05820","article-title":"CCI-779 Inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR\/HIF-1alpha\/VEGF signaling","volume":"8","author":"Wan","year":"2006","journal-title":"Neoplasia"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib18","first-page":"1527","article-title":"Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib19","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000101008","article-title":"CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model","volume":"79","author":"Thallinger","year":"2007","journal-title":"Pharmacology"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib21","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/sj.jid.5700872","article-title":"Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice","volume":"127","author":"Thallinger","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib22","first-page":"964","article-title":"Rapamycin and CCI-779 suppress the growth of hepatocellular carcinoma cells [abstract 4071]","volume":"47","author":"Hui","year":"2007","journal-title":"Proceedings of the 99th Annual Meeting of the American Association of Cancer Research"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib23","first-page":"312","article-title":"Antitumor effects of sorafenib, bevacizumab and cetuximab as single agents or in combination with an MEK, mTOR or bcl-2 inhibitor, in a SNU-398 human hepatocellular tumor xenograft model [abstract 1332]","volume":"48","author":"Rodon","year":"2008","journal-title":"Proceedings of the 99th Annual Meeting of the American Association of Cancer Research"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib24","first-page":"350","article-title":"Antiproliferative effects of a novel mTOR inhibitor (temsirolimus) in esophageal cancer cells [abstract 1493]","volume":"48","author":"Nishikawa","year":"2008","journal-title":"Proceedings of the 99th Annual Meeting of the American Association of Cancer Research"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib25","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-06-2449","article-title":"Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer","volume":"67","author":"Nathan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjc.6603656","article-title":"Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy","volume":"96","author":"Jimeno","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib27","first-page":"97","article-title":"CCI-779 a promising radiosensitizer for head and neck squamous cell carcinoma when compared to cisplatin [abstract 420]","volume":"48","author":"Ekshyyn","year":"2008","journal-title":"Proceedings of the 99th Annual Meeting of the American Association of Cancer Research"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","article-title":"The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL","volume":"107","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib30","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib31","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","article-title":"Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib33","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1158\/1078-0432.CCR-06-1331","article-title":"Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma","volume":"12","author":"Francis","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib34","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","article-title":"A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis","volume":"68","author":"Shor","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib35","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib36","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Podsypanina","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib37","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib38","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib39","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib41","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med Oncol"},{"issue":"suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib44","first-page":"262s","article-title":"Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract 5050]","volume":"26","author":"Logan","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib45","article-title":"Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma","author":"Gerullis","year":"2009","journal-title":"Med Oncol"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.010_bib46","first-page":"141s","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract 3512]","volume":"25","author":"Patnaik","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.010_bib48","first-page":"243s","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract 5034]","volume":"25","author":"Merchan","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"issue":"suppl 15s","key":"10.1053\/j.seminoncol.2009.10.010_bib49","first-page":"244s","article-title":"Phase I\/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients [abstract 5039]","volume":"27","author":"Merchan","year":"2009","journal-title":"J Clin Oncol 2009 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","article-title":"Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme","volume":"23","author":"Chang","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib51","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib52","first-page":"196","article-title":"Pten signaling in gliomas","volume":"4","author":"Knobbe","year":"2002","journal-title":"Neurooncology"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/B:DRUG.0000036685.72140.03","article-title":"Phase I\/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs","volume":"22","author":"Chang","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib54","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0091270007306957","article-title":"Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications","volume":"47","author":"Boni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib55","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/1078-0432.CCR-07-0781","article-title":"Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma","volume":"13","author":"Kuhn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib56","first-page":"25","article-title":"Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02) [abstract 2057]","author":"Robins","year":"2007","journal-title":"J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib58","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib59","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib60","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib61","article-title":"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer","author":"Buckner","year":"2009","journal-title":"Invest New Drugs"},{"issue":"suppl 16s","key":"10.1053\/j.seminoncol.2009.10.010_bib62","first-page":"19s","article-title":"Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer [abstract 564]","volume":"23","author":"Carpenter","year":"2005","journal-title":"J Clin Oncol, 2005 ASCO Annual Proceedings"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2009.10.010_bib63","first-page":"S286","article-title":"Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract 6091]","volume":"100","author":"Chow","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib64","first-page":"41s","article-title":"Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab [abstract 1003]","volume":"26","author":"Andr\u00e9","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings"},{"issue":"suppl 15s","key":"10.1053\/j.seminoncol.2009.10.010_bib65","first-page":"13s","article-title":"Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer [abstract 530]","volume":"26","author":"Baselga","year":"2008","journal-title":"J Clin Oncol 2008 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib66","doi-asserted-by":"crossref","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor","volume":"13","author":"Rowinsky","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib67","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib68","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/sj.leu.2404217","article-title":"Synergy between an IGF-1R antibody and Raf\/MEK\/ERK and PI3K\/Akt\/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells","volume":"20","author":"Bertrand","year":"2006","journal-title":"Leukemia"},{"issue":"suppl 18s","key":"10.1053\/j.seminoncol.2009.10.010_bib69","first-page":"121s","article-title":"Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer\u2013NCIC IND 160 [abstract 3003]","volume":"24","author":"Oza","year":"2006","journal-title":"J Clin Oncol 2006 Annual Proceedings"},{"issue":"part I, suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib70","first-page":"296s","article-title":"A phase II study of temsirolimus (CCI-779) in patients with metastatic and\/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b [abstract 5516]","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol 2008 ASCO Annual Meeting Proceedings"},{"issue":"part I, suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib71","first-page":"293s","article-title":"A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC) [abstract 5502]","volume":"26","author":"Slomovitz","year":"2008","journal-title":"J Clin Oncol 2008 ASCO Annual Meeting Proceedings"},{"issue":"part I, suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib72","first-page":"160s","article-title":"Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179 [abstract 3558]","volume":"27","author":"Oza","year":"2009","journal-title":"J Clin Oncol 2009 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib73","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.21265","article-title":"CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium","volume":"104","author":"Margolin","year":"2005","journal-title":"Cancer"},{"issue":"part I, suppl 16S","key":"10.1053\/j.seminoncol.2009.10.010_bib74","first-page":"622s","article-title":"A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patents with extensive stage small cell lung cancer in remission after induction chemotherapy","volume":"23","author":"Pandya","year":"2005","journal-title":"J Clin Oncol 2005 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib75","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2001.19.8.2114","article-title":"Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593\u2014a phase III trial of the Eastern Cooperative Oncology Group","volume":"19","author":"Schiller","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1053\/j.seminoncol.2009.10.010_bib76","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1097\/01.JTO.0000283298.56701.a0","article-title":"A phase II NCCTG window of opportunity front-line study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC [abstract]","volume":"2","author":"Molina","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2009.10.010_bib78","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib79","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"issue":"part I, suppl 18S","key":"10.1053\/j.seminoncol.2009.10.010_bib80","first-page":"521s","article-title":"A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) [abstract 9504]","volume":"24","author":"Okuno","year":"2006","journal-title":"J Clin Oncol 2006 Annual Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib81","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib82","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib83","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib84","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib85","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"part I, suppl 15S","key":"10.1053\/j.seminoncol.2009.10.010_bib86","first-page":"457s","article-title":"Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract 8514]","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol 2008 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib87","first-page":"112","article-title":"Dual proteasome and mTOR inhibition promotes apoptosis in non-Hodgkin lymphoma cell lines [abstract 5039]","author":"Shanks","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib88","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1074\/jbc.M200043200","article-title":"Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6","volume":"277","author":"Shi","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib89","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/sj.onc.1210019","article-title":"AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells","volume":"26","author":"Frost","year":"2007","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib90","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.leukres.2009.01.039","article-title":"Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma","volume":"33","author":"Farag","year":"2009","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2009.10.010_bib91","first-page":"112","article-title":"Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and\/or refractory multiple myeloma [abstract 3696]","author":"Ghobrial","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T04:14:53Z","timestamp":1558671293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":90,"alternative-id":["S0093775409001924"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.10.010","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}